Atlas Trials

Study of HuL001 in Relapsed/Refractory Multiple Myeloma Patients

Clinical trial NCT07210047 · ENROLLING_BY_INVITATION

Trial details

NCT number
NCT07210047
Sponsor
HuniLife Biotechnology, Inc.
Status
ENROLLING_BY_INVITATION
Phase
Phase 1, Phase 2
Study type
INTERVENTIONAL
Multiple Myeloma Refractory
Start date
2025-08-18
Primary completion
2027-11-30
Enrollment
21

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.